Table 5.
Survival analysis of patients with oral squamous cell carcinoma according to clinicopathologic parameters and systemic inflammatory markers.
| Variables | Disease-Specific Survival | Progression-Free Survival | ||||
|---|---|---|---|---|---|---|
| Univariate Analysis |
Multivariate Analysis | Univariate Analysis |
Multivariate Analysis | |||
| p | p | Hazard Ratio (95% CI) | p | p | Hazard Ratio (95% CI) | |
| Age (>55 years) | 0.1293 | 0.2252 | 1.38 (0.82–2.34) | 0.1329 | 0.3500 | 1.23 (0.79–1.92) |
| Gender (Male) | 0.2874 | 0.9221 | 0.97 (0.54–1.73) | 0.3462 | 0.7593 | 0.93 (0.58–1.48) |
| T stage (reference 1) | <0.0001 | 0.8286 | <0.0001 | 0.6317 | ||
| 2 | 0.6694 | 0.62 (0.07–5.63) | 0.9388 | 0.92 (0.11–7.81) | ||
| 3 | 0.4558 | 0.39 (0.03–4.70) | 0.8899 | 1.18 (0.12–11.61) | ||
| 4 | 0.6402 | 0.54 (0.04–7.15) | 0.5508 | 2.04 (0.20–21.25) | ||
| N stage (reference 0) | <0.0001 | 0.6277 | <0.0001 | 0.9787 | ||
| 1 | 0.1091 | 0.32 (0.08–1.29) | 0.6247 | 0.77 (0.27–2.17) | ||
| 2 | 0.6264 | 0.69 (0.15–3.13) | 0.6875 | 0.77 (0.21–2.78) | ||
| 3 | 0.6979 | 0.76 (0.18–3.12) | 0.8974 | 0.92 (0.27–3.10) | ||
| 4 | 0.9726 | 0.00 (0–1000) | 0.9609 | 0.00 (0–1000) | ||
| DOI (>1 cm) | <0.0001 | 0.4120 | 1.75 (0.46–6.60) | <0.0001 | 0.7644 | 0.86 (0.32–2.33) |
| Stage (reference I) | <0.0001 | 0.3739 | <0.0001 | 0.7194 | ||
| II | 0.4611 | 2.53 (0.22–29.72) | 0.7179 | 1.52 (0.16–14.96) | ||
| III | 0.2311 | 4.22 (0.40–44.57) | 0.5945 | 1.83 (0.20–16.92) | ||
| IV | 0.1079 | 8.59 (0.62–118.32) | 0.3427 | 3.19 (0.29–34.96) | ||
| Lymphatic invasion | 0.00086 | 0.1813 | 1.56 (0.81–2.98) | 0.0010 | 0.0757 | 1.64 (0.95–2.84) |
| Vascular invasion | 0.7050 | - | - | 0.6535 | - | - |
| Perineural invasion | <0.0001 | 0.1651 | 1.51 (0.84–2.71) | 0.0030 | 0.9179 | 1.03 (0.62–1.70) |
| Differentiation (reference well) | 0.0022 | 0.0663 | 0.0025 | 0.1059 | ||
| Moderate | 0.4403 | 0.80 (0.46–1.41) | 0.8445 | 1.05 (0.66–1.65) | ||
| Poor | 0.0622 | 2.33 (0.96–5.67) | 0.0380 | 2.28 (1.05–4.97) | ||
| Platelet high | 0.0013 | 0.1474 | 1.60 (0.84–3.00) | 0.0093 | 0.5314 | 1.20 (0.68–2.13) |
| NLR high | 0.1221 | - | - | 0.0485 | 0.4553 | 1.25 (0.69–2.27) |
| PLR high | 0.0004 | 0.0064 | 2.33 (1.27–4.28) | 0.0020 | 0.0300 | 1.80 (1.06–3.06) |
| SII high | 0.0119 | 0.6822 | 0.88 (0.46–1.65) | 0.0174 | 0.5836 | 0.83 (0.44–1.59) |
| SIRI high | 0.0949 | - | - | 0.1326 | - | - |
CI, confidence interval; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic inflammation index; SIRI, systemic inflammation response index. In univariate analysis, T stage, N stage, depth of invasion, AJCC stage, lymphatic invasion, perineural invasion, tumor differentiation, and platelet count were associated with DSS and PFS (all p < 0.05).